glp 1 shortage fda The GLP-1 drug is over. What's next for the compounders? - Pharma Technology Focus | Issue 154 What Changed? The FDA's Clarification
Description
To harness the promising effects of GLP-1 for the development of a clinically useful drug, the short duration of action needed to be overcome
According to the FDA prescribing information, nausea occurs in approximately 15-30% of patients, vomiting in 6-12%, and diarrhea in 13-24% (rates vary by dose and indication)
When hair loss occurs, I check for possible vitamin and iron deficiencies, which can be associated with hair loss
The early signs are easy to brush off
